01528nam a2200265 4500 ESSALUD 20260903093950.0 ta t pe ||||| |||| 00| 0 spa d BMG eng Der, Channing J. Autor 54512 Advances in RAS therapeutics for pancreatic cancer páginas: 1857-1861 Somatic mutations in the Kirsten rat sarcoma viral oncogene homologue (KRAS) occur in more than 90% of pancreatic ductal adenocarcinomas. In this issue of the Journal, Wolpin et al. evaluated the side-effect profile of and response to a first-in-class small-molecule drug called daraxonrasib, which targets the active state of RAS (see Key Concepts) in patients with metastatic pancreatic ductal adenocarcinoma who have received at least one previous line of chemotherapy. In the context of second-line treatment, they reported an objective response according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, in up to 35% of patients and a median response duration of 8.2 months. CÁNCER 1231 CÁNCER DEL TRACTO GASTROINTESTINAL 53776 GASTROENTEROLOGÍA 12562 HEMATOLOGÍA 7422 ONCOLOGÍA 12240 GENÉTICA GENERAL 54107 Yeh, Jen Jen 54513 22717 22676 Massachusetts NEJM Group NEJM015 The New England Journal of Medicine ESSALUD 0028-4793 ARTICULOS 2026-08-31 sqb 22915 22915